dilemmas of the upper gi tract - ucsf cme
TRANSCRIPT
1
Dilemmas of the Upper GI Tract
Jeffrey Fox, MD, MPH UCSF Primary Care Medicine:
Update 2013
I have no conflicts of interest to disclose
Art Byrne
• 42 yo white overweight male • Has substernal burning once per week
before he goes to sleep at night for 10 years
• No dysphagia, weight loss, early satiety, blood in stool, or jaundice
• Responds to self-use of antacids • Flares of symptoms correlate with stress
What should we recommend?
A. Anti-reflux behavioral management only B. Upper endoscopy C. Test for H.pylori and treat if positive D. Trial of H2RB + behavioral measures E. Trial of PPI + behavioral measures
2
Art Byrne questions
• When is it OK to do empiric therapy for his symptoms without further evaluation?
• What therapy should we choose? • When do we need to do endoscopy? • Is it safe to use proton-pump inhibitors
long-term? • Does stress play a role?
GERD burden (GERDen)
• Very common • 25% of Americans use antacids/
antisecretory meds ≥3X/mo • $8 billion/year spent antacids/H2RB/PPI • Detrimental effects on quality of life found
with symptoms as infrequent as once weekly
Ronkainen et.al. Aliment Pharmacol Ther 2006
3
The Gallup Organization, 1988
MONTHLY GERD SYMPTOMS
Locke, Gastroenterol, 1997
WEEKLY GERD SYMPTOMS
Nebel, et.al. Am J Dig Dis, 1976
DAILY GERD SYMPTOMS BARRETT’S ESOPHAGUS
Ronkainen et al, Gastroenterol 2005
4
ESOPHAGEAL ADENOCARCINOMA ESOPHAGEAL ADENOCARCINOMA
1 in 20,000
Sharma et.al., Gastroenterol, 2006
Defining GERD • Symptom pattern – heartburn, regurgitation,
dysphagia – How often is “disease”
• Pathologic lesion – erosive esophagitis – Combo of symptoms and esophagitis highly
specific (97%) vs. pH testing – What about those with the symptoms but
without the lesion – “NERD” • “Gold-standard” – pH monitoring best but
imperfect
Whom should I treat empirically?
• Typical symptoms • No alarm features • At least partial relief with OTC measures • Age <55
5
Lifestyle measures
• Raise head of bed • Don’t eat late; >3 hours between meal and
bedtime • Avoid fatty foods, caffeine, alcohol, citrus,
tomato, peppermint • Stop smoking • Weight loss • Stop offending meds
Lifestyle measures
• Systematic review of effectiveness of common measures in reducing symptoms – Randomized controlled trials: NONE – Retrospective/case-control studies:
• Elevating head of bed – yes • Sleeping in left lateral decubitus position – yes • Losing weight – yes (Now USPSTF grade B rec) • Dietary measures – No (!!)
– Included tobacco/alcohol cessation
Kaltenbach, et.al. Arch Intern Med, 2006
Empiric therapy
• H2RAs (ie H2 blockers) • “Step-up approach” • Eliminate symptoms in 50% with BID dosing • Maintains remission in only about 25% of patients • Appropriate empiric therapy in setting where cost
difference between H2RA and PPI is large
Empiric therapy
• PPIs • Effective for symptom relief and esophagitis in
85-90% once-daily dosing • PPI “test” 83% sensitive compared to pH probe/
esophagitis “gold standard”
• In primary care GERD symptom population, likelihood ratio of positive PPI test 1.2 (CI 0.9-1.6) for pH-proven GERD relative to negative PPI test
Fass, et.al. Aliment Pharacol Ther, 2000
Aanen, et.al. Aliment Pharacol Ther, 2006
6
PPIs: Which one?
• 6 agents (omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole) all FDA approved and effective for GERD
• Esomeprazole (Nexium) decreases number hrs pH held above 4 at standard doses and heals esophagitis in slightly higher % of patients than others
Miner,et al. Am J Gastroenterol, 2003
PPIs: Which one?
• However, NO AGENT SUPERIOR for symptom relief when agents compared head to head.
HENCE: • Choose the one on formulary; otherwise,
would choose omeprazole because generic
7
PPIs: How long?
• Erosive esophagitis – 8 weeks • Barrett’s esophagus – lifetime • GERD symptoms – 4-8 weeks, then stop
to see if strict behavioral measures will be effective
• Many need long-term maintenance therapy
GERD relapses after cessation of therapy
Sandmark, et.al. Scand J Gastroenterol, 1988
Long-term PPI Safety
• Endocrine – Serum gastrin elevated – theoretical “trophic” risk in
gestation – 1st trimester pregnancy use: no increase in
birth defects – Gastric carcinoids in rats, no cancer increase in
humans • Nutritional
– Can lower cobalamine (B12) absorption – Not thought to significantly affect iron homeostasis
Dent, et.al. Gut, 1994 Klinkenburg-Knol, et.al. Ann Int Med, 1994
Pasternak B, et al. NEJM, 2010
Fiocca R et al. Alim Pharmacol Ther 2012
Long-term PPI Safety
• Hip fracture – Case/control study in UK
Duration Hip fracture of therapy Adjusted OR (CI) 1yr 1.22 (1.15-1.30) 2yr 1.41 (1.28-1.56) 3yr 1.54 (1.37-1.73) 4yr 1.59 (1.39-1.80)
Yang et.al. JAMA 2006
8
Long-term PPI Safety
• Hip fracture – Higher risk for “high dose” (over 1.75 doses per day)
• OR 2.65 for high dose/long term – Lower risk for H2RB though still statistically significant
increased risk. – Cases also were more likely than controls to take:
anxiolytics (OR 1.76), antidepressants (2.17), NSAIDs (1.38), antipsychotics (3.34), antiseizure meds (3.42), antiparkinsonian meds (3.83), corticosteroids (2.25), and thyroxine (1.40)
Yang et.al. JAMA 2006
Long-term PPI Safety
• Hip fracture – Higher risk for “high dose” (over 1.75 doses per day)
• OR 2.65 for high dose/long term – Lower risk for H2RB though still statistically significant
increased risk. – Cases also were more likely than controls to take:
anxiolytics (OR 1.76), antidepressants (2.17), NSAIDs (1.38), antipsychotics (3.34), antiseizure meds (3.42), antiparkinsonian meds (3.83), corticosteroids (2.25), and thyroxine (1.40)
Yang et.al. JAMA 2006
2010 FDA warning
Long-term PPI safety
• Nurses health study – Prospective cohort study – 565,786 person-years follow-up – Hip-fracture risk
• Current PPI users 2/1000 person-years • Non-users 1.5/1000 p-y
– Attributable risk 1/2000 p-y – Adjusted HR 1.35
• Risk disappears after 2 years cessation • Smoking appears to be cofactor
1Khalili H, et al. BMJ 2012
Long-term PPI Safety
• Why fractures? – Theoretically, acid inhibition interferes with
calcium absorption in the small intestine – However, PPIs do NOT appear to be
associated with osteoporosis or accelerated bone mineral density loss
– Confounders? – Osteoclast proton-pump inhibition?
Targownik LF, et al. Gastroenterol, 2010 Targownik LF, et al. Am J Gastroenterol 2012
9
Long-term PPI Safety
• Community-acquired infections – Clostridium difficile: Case/control study in UK1
• For people taking PPIs: OR 2.9 • For people taking H2RBs: OR 2.0
– Community acquired pneumonia: meta-analysis of case-control studies2
• OR for CAP 1.36 for PPI relative to controls • Significant heterogeneity and only modest risk
– Theoretical basis is decrease in gastric acidity may be “permissive” to enteric infection (in Cdiff) and reflux/microaspiration (CAP)
Dial et.al. JAMA 20051
Johnstone J, et.al. Aliment Pharmacol Ther 20102
Long-term PPI safety
• Hypomagnesemia – FDA safety alert March 2011: Hypomagnesemia is rare but possible adverse effect from long-term PPI use
– Special care in patients also on other meds that can cause hypoMg (eg diuretics, digoxin)
– Can result in muscle spasm, seizures, and cardiac events
What about PPIs and Plavix? • Plavix effect on platelets thought to be
mitigated by PPIs in ex-vivo platelet aggregation studies (P450 CYP2C19)
• Observational data mixed on event rates
• Randomized trial of PPI + plavix vs. plavix alone (COGENT) – no difference in cardiac events – PPI/plavix group had 50% bleeding risk
Bhatt, et al. NEJM 2010
Ho PM et al, JAMA 2009 Ray WA et al. Ann Intern Med 2010 Banergee S et al. Am J Cardiol 2011
ACC/AHA/ACG position • In patients taking clopidogrel+ASA
– 2008 – ACC/AHA/ACG “take PPI co-therapy” – 2009 – FDA BOXED WARNING on
omeprazole/esomeprazole plus clopidogrel – 2010 – ACC/AHA/ACG position update:
• There may be an important interaction • In high risk patients for UGI bleed, benefits of PPI
co-therapy outweigh risks • In average risk patients, case-by-case approach • Use non-omeprazole/esomeprazole PPIs when on
plavix if PPI is needed/advised
10
PPI vs aspirin
• Number needed to harm (NNH) = number of people who need to be prescribed medication to have 1 complication above the level of non-users – GI hemorrhage on annual basis with aspirin
treatment: NNH 247-833 – Hip fracture on annual basis with PPI
treatment: NNH 20001
1Khalili H, et al. BMJ 2012
Long-term PPI Safety
Still overall good safety profile • No randomized data proving harm • Enough retrospective or non-randomized
prospective evidence of potential harm to be judicious
• Needs further study Questions raised in a given patient: • Does my patient need this medication? • What is the lowest effective dosage for shortest
time necessary?
PPI maintenance: On-demand • Symptom-driven therapy
– Single-dose (true “on-demand”) – Short course (“intermittent therapy”)
• Controlled by patients, not providers • PPI on-demand therapy may be most
cost-effective of all maintenance strategies – Fewer meds, adverse reactions, and OVs – Lower overall healthcare costs
• 2011: FDA lifted PPI fracture warning for OTC
Gerson, et.al. Am J Gastroenterol, 2000
Other PPI recommendations
• If long-term usage deemed necessary: – Calcium/Vitamin D supplementation – Weight bearing exercise – Periodically monitor vitamin B12
11
Refractory patients • Standard dosing regimen once-daily not working for
“classic” symptoms after 1 month trial once-daily PPI • OPTIONS:
– Twice-daily (breakfast/dinner) eg omeprazole 20 BID – Add H2RA for nocturnal acid breakthrough
• Recently shown to be of little benefit, but anecdotally some improve
– Twice-daily double dose (eg omeprazole 40 BID) • Can be helpful in subset
– Other agents: sucralfate, prokinetics, (treat concomitant gastric emptying disorder), baclofen
Vakil et.al. Aliment Pharmacol Ther, 2006
Leite, et.al. Am J Gastroenterol, 1996
GERD and stress
• Animal model – Rats subjected to stress have more
esophageal mucosal permeability and dilated intercellular spaces relative to controls
• Acid exposure in humans is similar in stress and non-stress, but perception of acid higher in stress
Farre R et.a. Gut 2007
Non-erosive GERD: NERD! • “Endoscopy-negative GERD”, “functional heartburn”,
“IBS of the esophagus” • 50-70% of those with classic GERD symptoms • Less likely to have abnormal pH study • Mechanisms
– Hypersensitivity – Disordered motility – Psychological factors
• High correlation with female gender, functional GI disorders, mood disorders
• Can respond to mix of acid reducing meds, antidepressants, anxiolytics, psychotherapy
Chey WD, Am J Med, 2004
SSRI and NERD
Viazis N et al. Am J Gastroenterol 2012
• 75 patients with hypersensitive esophagus (reflux symptoms > 6 mo, refractory to BID PPI, negative endoscopy and pH study) randomized to citalopram 20mg once daily or placebo
Citalopram Placebo Reflux symptoms at 6 months 38.5% 66.7%
P=0.021
12
• If GERD-like symptoms but no better on acid reduction:
• STOP/REDUCE ACID REDUCTION THERAPY
• TRY SOMETHING ELSE
Meds don’t work: What else?
• Referral to specialist • Anti-reflux surgery • Psychological/psychotropic therapy • Naturopathic/alternative
GERD – alarm symptoms
• Dysphagia • Odynophagia • Weight loss • Bleeding (melena, hematemesis) • Anemia • Anorexia • Nausea/vomiting • Severe or persistent symptoms despite Rx
The further evaluation…
• Endoscopy • Ambulatory pH testing/impedence testing • Esophageal manometry • Barium esophagram • Other
– Laryngoscopy – Cardiac stress testing – PFTs – Serum gastrin
13
Endoscopy referral for GERD ACP guidelines 2012
• Heartburn plus alarm symptoms
• Persistent symptoms despite adequate therapy for 4-8 weeks
• Severe erosive esophagitis despite 2 months hi-dose PPI
• History of esophageal stricture with recurrent dysphagia
• Established Barrett’s esophagus
• Select men > age 50 with additional risk factors (eg obesity, smoking, nocturnal symptoms)
Shaheen N et al. Ann Intern Med 2012
Anti-reflux surgery
• Defect in mechanical barrier to reflux corrected • Laparoscopic Nissen fundoplication • Success largely operator dependent • Best candidates: those with GERD on both
subjective and objective measures • Poor candidates: poor surgical candidates,
atypical symptoms • Initial success 90-95% in eliminating sx and
healing esophagus (many studies)
Medical vs. Surgical Rx • 10-13 year follow-up • No significant difference
between medical and surgical arms in physical and mental well-being or overall satisfaction
• 62% of surgical patients taking meds for GERD symptoms
• ?increased mortality in surgical arm
Spechler, et.al. JAMA 2001
14
GERD and asthma
• Acid reflux can cause bronchoconstriction • NIH asthma guidelines recommend
investigating GERD in asthma patients, even without GERD symptoms
• Randomized trial Nexium vs placebo in asthmatics with no or minimal GERD sx – No difference between groups in symptoms or
PFTs, even those with silent reflux
American Lung Association Asthma Clinical Research Centers, NEJM, 2009
GERD and extraesophageal sx
• Laryngitis, chronic cough, asthma • USPSTF position:
– Treatment recommended when extraesophageal symptoms accompany typical esophageal symptoms (grade B)
– Treatment not recommended in absence of typical esophageal symptoms (grade D)
Kahrilas PJ, et al. Gastroenterol 2008
Remember…
• GERD is chronic disease – meds control most people’s symptoms to a manageable level (75-80% improvement) but do not eliminate them – Reassurance is enormous part of job
• Empiric therapy appropriate for uncomplicated disease; alarm symptoms should warrant GI referral
• PPIs are OK but stop if not helping
Barrett’s esophagus covered in “GI malignancies” talk
15
Bill Leeder
• 68 yo male with CAD, severe osteoarthritis, and depression comes to your for post-hospitalization visit
• Recent admission for UGI bleed from gastric ulcer
• Takes baby aspirin, ibuprofen, and zoloft in addition to newly started omeprazole; he was told to stop some medication but cannot remember which one
Which agent placed him at risk for GI bleeding?
A. Baby aspirin B. Ibuprofen C. Zoloft D. Baby aspirin and Ibuprofen E. All of the above
Medications and UGI bleeding
COX-2 inhibitors and GI safety • Main advantage of COXIBs has been fewer
peptic ulcers and better tolerability than non-selective NSAIDs – Supported by recent Cochrane Meta-Analysis – Compared to standard NSAIDs, COXIBs had:
• Fewer gastroduodenal ulcers (RR 0.26; CI 0.23-0.3) • Fewer ulcer complications (RR 0.39; CI 0.31-0.5) • Fewer withdrawals for GI sx (RR 0.65;CI 0.57-0.73) • Fewer GI bleed events (upper AND lower)
– Need to weigh higher cardiovascular risk, which appears to be directly correlated to degree of Cox-2 selectivity
Rostom A, et.al. Clin Gastroenterol Hepatol 2007
16
Ray WA, et.al. Gastroenterol 2007
PPI gastroprotection • NOT FOR MAJORITY OF PATIENTS • ACG guidelines 2009
– High risk • Hx of complicated peptic ulcer disease or • More than 2 risk factors (below)
– Moderate risk (1-2 risk factors) • Age >65 • High-dose NSAIDs • Hx of uncomplicated ulcer disease • Use of aspirin, corticosteroids, or anticoagulants
– Low risk • None of the above
SSRIs and UGI bleeding
• Current, recent, or past SSRI use is associated with a 1.67, 1.88, and 1.22 OR of an UGI bleed
• Risk was increased with concurrent use of NSAIDs or anti-platelet therapy and decreased with concurrent use of PPI
• TCAs did not show this association • Inhibition of platetet activity possible
mechanism Dall M, et al. Clin Gastroenterol Hepatol 2009
Low dose aspirin and GIB
• Meta-analysis of dosages 75-325mg/day RR*
– Decreased overall mortality 0.93
– Increased risk of GI bleeding 1.55
– In combination with aspirin, vs aspirin alone • Other antiplatelet/anticoagulants 1.86 • PPI 0.34
*All statistically significant
Lanas A et al. Clin Gastroenterol Hepatol 2011
17
Stopping aspirin after GI bleed?
PPI plus baby aspirin PPI plus placebo
Rebleed risk after 8 weeks 10% 5%
All-cause mortality after 8 weeks 1% 13%
Patients with peptic ulcer bleed on aspirin Randomized to PPI + aspirin vs. PPI + placebo
Sung, JJY, et.al, Ann Int Med, 2010
Stopping meds after GI bleed
• Within 1 year of GI bleed, many patients are re-started on the offending medication SSRIs – 82% NSAIDs – 25% Warfarin – 58% Clopidogrel – 55% – Many patients end up on offending medication
plus PPI for gastroprotection • 20-25% were not
– Poor communication between inpatient and outpatient/primary care systems?
Dall M et al. Aliment Pharmacol Ther 2012
http://www.asariskcalculator.com
http://www.asariskcalculator.com Lanas A et al. Aliment Pharmacol Ther 2013
18
Billie Aiken
• 38 yo black woman comes into your office with epigastric pain, non-radiating, constant, inconsistently associated with meals for months
• She was born in Haiti but moved to this country when she was 10
• Denies any blood in stool, early satiety • She takes no medications • Only medical problem is IBS
Billie Aiken
• What is the most appropriate initial approach to her symptoms?
• How likely is she to have H.pylori? • What is the relevance of the IBS?
Dyspepsia Pain or discomfort in
epigastrium
19
Approach to dyspepsia
• Numerous possible initial approaches – H.pylori test and treat – Empiric antisecretory (H2RB or PPI) – Endoscopy
Which of the following are not Group 1 (proven) carcinogens:
A. Human Immunodeficiency Virus (HIV) B. Human Papilloma Virus (HPV) C. Hepatitis B Virus (HBV) D. Helicobacter pylori (H.pylori) E. All of the above are considered Group 1
carcinogens
H.pylori: Who has it?
• Prevalence in adults in mid 1990s – 50% developed world – 80% developing world
• Risk factors – Lower socioeconomic status – Poor living conditions, eg crowding, lack of
running water, housing density
Pounder RE, et.al. Aliment Pharmacol Ther 1995
H.pylori and ethnicity • NHANES stored sera from 1988-1991
Everhart JE et.al. J Infect Dis 2000
Non-Hispanic White
Mexican American
African American
Prevalence 26.2% 61.6% 52.7%
Odds ratio compared to
White NA 6.3 (4.8 - 8.3) 3.9 (3.1 - 4.9)
20
H.pylori: Declining prevalence
• Within a given country, appears to relate to improvements in economic status and sanitation – In Japan, H.pylori seropositivity
• Born prior to 1950: > 70% • Born 1950-1960: 45% • Born after 1960: 25%
Asaka M, et.al. Gastroenterology 1992
H.pylori associations
• Duodenal and gastric ulcers • Gastric cancer
– MALT – Gastric adenocarcinoma – Atrophic gastritis/gastric intestinal
metaplasia • Functional dyspepsia
H.pylori and ulcers
• Strong association between H.pylori and duodenal ulcers, less strong for gastric ulcers
• Synergistic effect with H.pylori and NSAIDs in ulcer incidence
• Effective eradication of H.pylori clearly reduces ulcer recurrence
Does H.pylori cause gastric cancer?
• Direct damage to mammalian epithelial DNA has been shown
• Patients with H.pylori infection have a higher rate of gastric adenocarcinoma than patients without1
• Treatment of H.pylori in MALT lymphoma when early stage can be curative
1Toller IM, et. Al. Proc Nat Acad Sci, 2011
21
Does eradicating H.pylori reduce risk of cancer?
• Meta-analysis of follow-up from 6 randomized controlled treatment trials – Mean 4-10 years of follow up – 6,695 patients
Treated Untreated Developed gastric adenocarcinoma 1.1% 1.7%
Relative risk of gastric cancer: 0.65 (95% CI 0.43-0.98)
Fuccio L et.al. Ann Intern Med 2009
H.pylori and functional dyspepsia
• Controversial association between functional dyspepsia (FD) and H.pylori
• Evidence that H.pylori eradication in FD improves symptoms is mixed
• Meta-analysis shows SMALL but statistically significant improvement in HP eradication in FD1 – NNT 18 for 1 improvement over placebo
1Moayyedi P, et.al. Cochrane Database Syst Rev 2005
H.pylori testing
• Serology • Urea breath test • Stool antigen • Endoscopic biopsy
– Histology – Culture
22
H.pylori testing
• Serology test/treat • Urea breath test • Stool antigen • Endoscopic biopsy
– Histology – Culture
Check eradication or for recurrent symptoms post-eradication
H.pylori testing
• Serology test/treat • Urea breath test • Stool antigen • Endoscopic biopsy
– Histology – Culture
Check eradication or for recurrent symptoms post-eradication
H.pylori testing caveats
• Serology positive for life, does not separate current from past infection – Not useful as serial test
• PPIs cause false negative of urea breath test and stool antigen test – Must be off PPIs for at least 2 week to avoid
false negative results
H.pylori treatment • First-line therapy (AOC) X 10-14 days1
– Amoxacillin 1000mg BID – Clatrithomycin 500mg BID – PPI standard dose BID
• PCN allergic: Switch Flagyl 500mg BID for Amoxacillin
• 7 days nearly as effective as 10-14 days2
• Treatment-failures, numerous regimens 1Chey WD, et.al. Am J Gastroenterol 2007 2Fuccio L, et.al. Ann Intern Med 2007
Eradication
80%
23
H.pylori sequential vs standard Sequential
PPI + Amox X 5 days
then PPI + Biaxin
+ Flagyl X 5 days
Standard
PPI + Amox + Biaxin
X 14 days
Eradication (intention to
treat) 85.9% 75%
Eradication (per protocol) 92.6% 85%
• Resistance to standard “triple therapy” increasing
• Sequential therapy may improve eradication over standard triple therapy p = 0.006
Kim YS, et al. Aliment Pharmacol Ther 2011
p=0.019
H. Pylori and GERD • Try to distinguish GERD symptoms from
dyspepsia!! – Often difficult – overlapping and multiple
complaints – Poor correlation between patient & clinician
symptom assessement (kappa 0.17-0.53) – Treatment of H.pylori may WORSEN GERD
• H.pylori infection in some observational studies lower in patients with GERD symptoms
• Randomized trial did NOT confirm GERD higher in H.pylori treated patients
McColl, et.al. Am J Gastroenterol 2005 Moayyedi, et.al. Gastroenterol 2001
Will I miss cancer if no endo?
• 2,741 patients with dyspepsia without alarm symptoms – 6 cancers (3 gastric/3 esophageal) (0.2%)
• Only 1 cancer in patient under 50 • Cost per cancer $16,000 - $82,000
– 23.2% had any mucosal findings
Vakil N, et al. Clin Gastroenterol Hepatol 2009
Use of endoscopy in dyspepsia
• Always with alarm symptoms – Alarm symptoms poor predictor of organic
pathology • Failure to improve despite empiric therapy • Appropriate age “cut off” is controversial
– Guidelines vary from 45-55 – UGI cancer rare prior to age 55
24
How to approach a patient with dyspepsia
Dyspepsia
Endoscopy CBC/LFT/amylase/TTG Consider imaging if WL
All explanations considered? *Med side effect *Biliary source
*Cardiac source
Test and treat
Address specific findings
H. pylori likely?
Empiric anti-secretory therapy
Treat functional dyspepsia Endoscopy Monitor for
recurrent symptoms
Alarm symptoms or age > 55? yes no
normal
abnormal yes no
no yes
Symptom resolution?
neg
findings
yes no
Functional dyspepsia • Pain in epigastrium without identifiable “organic
cause” (endoscopy negative) • What’s wrong then? Not clear.
– Motility disorder? – Visceral hypersensitivity? – Psychosocial factors? – Altered brain-gut axis?
• Overlap with other functional GI disorders (eg NERD, IBS)1
• 2/3 of pts presenting with dyspepsia have FD
1Corsetti M et.al. Am J Gastroenterol 2004
Functional dyspepsia: Medical Management
Saad RJ, et.al. Aliment Pharmacol Ther 2006
Therapy NNT PPI 9
H.pylori eradication 18 Prokinetics 4 (included cisapride)
TCA/anxiolytics 4 Anatacids, bismuth, sucralfate No better than placebo
NNT = Number needed to treat = 1/effect size
25
Functional dyspepsia: Anything else?
• Psychotherapy – Individual trials suggest benefit – Systematic review unable to synthesize1
• Studies too diverse • High dropout rates in control groups
• Complementary alternative medicine2 – STW 5 (Iberogast) – Capsaicin – red chili pepper – Artichoke leaf extract
Soo S et.al. Am J Gastroenterol 20041 Saad RJ et.al. Aliment Pharmacol Ther 20062
Cannabinoid hyperemesis
• Cyclic N/V associated with epigastric pain • Long-term (>1 year) cannabis use
– At least weekly use, often daily • Relief with hot showers/baths • Resolution with cessation of cannabis • Also supportive but not essential: • Age under 50 • Weight loss > 5kg • Morning symptom predominance
• Normal bowel habits • Negative laboratory, radiographic,
and endoscopic test results
Simonetto DA, et al. Mayo Clin Proc, 2012
Cannabinoid hyperemesis
• Cyclic N/V associated with epigastric pain • Long-term (>1 year) cannabis use
– At least weekly use, often daily • Relief with hot showers/baths • Resolution with cessation of cannabis • Also supportive but not essential: • Age under 50 • Weight loss > 5kg • Morning symptom predominance
• Normal bowel habits • Negative laboratory, radiographic,
and endoscopic test results
Simonetto DA, et al. Mayo Clin Proc, 2012